Form 4: Arcutis Biotherapeutics Director Sue-Jean Lin Reports Significant Equity Grant

Arcutis Biotherapeutics, Inc. Director Sue-Jean Lin reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as part of her compensation for service.

Summary

• Sue-Jean Lin, a Director of Arcutis Biotherapeutics, Inc. (ARQT), acquired 7,609 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 12, 2025, at a grant price of $0.
• She also acquired 20,568 stock options on June 12, 2025, with an exercise price of $13.5 per share and a grant price of $0.
• The RSUs and stock options are compensation for her service as a non-employee director.
• Both the RSUs and stock options are scheduled to vest 100% on the earlier of the first anniversary of the grant date (June 12, 2026) or immediately before the Company's next annual meeting of stockholders, subject to continued service.
• The settlement of the RSUs has been deferred by Ms. Lin, pursuant to an RSU Deferral Election Form adopted on October 21, 2024.
• Following these transactions, Ms. Lin beneficially owns 26,735 shares of Common Stock and 20,568 stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a non-employee director, which is a positive for aligning interests with shareholders and demonstrating continued commitment. It is a standard governance practice and does not indicate any negative operational or financial issues.

Positives

• The grant of Restricted Stock Units and stock options to a non-employee director aligns her interests directly with those of the shareholders, encouraging long-term value creation.
• The deferred settlement of RSUs indicates a long-term commitment from the director to the company's success.

Future Outlook

The vesting schedule for the RSUs and stock options indicates a future increase in the director's vested equity holdings, contingent on continued service. The deferred settlement of RSUs suggests a long-term investment horizon for the director's compensation.

Industry Context

The grant of equity compensation, including Restricted Stock Units and stock options, to non-employee directors is a standard practice in the biotechnology and pharmaceutical industries. This approach is designed to align the interests of the board members with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The structure of compensation, involving a mix of Restricted Stock Units and stock options, is consistent with common practices for non-employee directors in the biotech sector.
• Specific quantitative comparisons to peer companies or projects are not possible based solely on the information provided in this Form 4 filing.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Management: The Power of Attorney grants specific company officers (CEO, CFO, General Counsel) the authority to execute and file SEC forms on behalf of the director, streamlining compliance.

Next Steps

• Vesting of 7,609 Restricted Stock Units on or after June 12, 2026, or immediately before the next annual meeting of stockholders.
• Vesting of 20,568 stock options on or after June 12, 2026, or immediately before the next annual meeting of stockholders.
• Potential future settlement of deferred Restricted Stock Units.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Insider Ownership, Sue-Jean Lin, SEC Form 4